NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
NRx Pharmaceuticals reported a Q1 2026 net loss of $1.4 million, a significant improvement from the $5.5 million loss in the prior year, driven by fair value accounting adjustments and non-recurring charges in 2025. The company highlighted substantial progress toward commercialization, including FDA acceptance of its ANDA for preservative-free ketamine (KETAFREE) with an anticipated decision in Q3 2026, and the initiation of commercial manufacturing at a scale of 1 million doses per month.
Key figures
- Revenue
- 0
- Atm Proceeds
- 7000000
- Cash And Equivalents
- 6700000
- Nd patient count
- 1,000
- Hope clinic count
- 5
- Rwe patient count
- 65,000
- Hope clinic target q2
- 8
- Manufacturing capacity
- 1 million doses per month
- Mind1 trial enrollment
- 400
- Spravato annual revenue
- $2 billion
- Generic ketamine market size
- $750 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.